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Background: Randomized controlled trials (RCTs) for determining 
efficacy of preexposure prophylaxis (PrEP) in preventing human 
immunodeficiency virus (HIV) infection have not been conducted 
among US women because their lower HIV incidence requires im-
practically large studies. Results from higher-incidence settings, like 
Sub-Saharan Africa, may not apply to US women owing to differ-
ences in age, sexual behavior, coinfections, and adherence.
Methods: We propose a novel strategy for evaluating PrEP efficacy in 
the United States using data from both settings to obtain four param-
eters: (1) intention-to-treat (ITT) and (2) per-protocol effects in the 
higher-incidence setting, (3) per-protocol effect generalized to the lower-
incidence setting, and (4) back-calculated ITT effect using adherence 
data from the lower-incidence setting. To illustrate, we simulated two 
RCTs comparing PrEP against placebo: one in 4000 African women and 
another in 500 US women. We estimated all parameters using g-compu-
tation and report risk ratios averaged over 2000 simulations, alongside 
the 2.5th and 97.5th percentiles of the simulation results.
Results: Twelve months after randomization, the African ITT and 
per-protocol risk ratios were 0.65 (0.47, 0.88) and 0.20 (0.08, 0.34), 
respectively. The US ITT and per-protocol risk ratios were 0.42 (0.20, 
0.62) and 0.17 (0.03, 0.38), respectively. These results matched well 
the simulated true effects.
Conclusions: Our simple demonstration informs the design of future 
studies seeking to estimate the effectiveness of a treatment (like PrEP) in 
lower-incidence settings where a traditional RCT would not be feasible. 
See video abstract at, http://links.lww.com/EDE/B506.
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Randomized controlled trials (RCTs) are the gold standard for determining the efficacy of a treatment, but varia-
tions in adherence can compromise the generalizability of 
RCT results to groups that differ from the study population 
in which the RCT was conducted. Adimora et al1 discussed 
an approach to estimate the intention-to-treat (ITT) effect in 
a target population whose outcome incidence is substantially 
lower than the incidence in the population where the treat-
ment was formally tested using a RCT. The authors outlined 
how to use key data from both samples, such as biologically 
determined adherence and baseline effect measure modifiers, 
and the per-protocol effect (i.e., the effect of remaining on 
trial protocol, usually of remaining adherent to the trial drug) 
as an intermediary step to obtain the desired estimates in the 
target population. The approach discussed by Adimora et al. 
is important when the event of interest is uncommon enough 
in the target population to render a local RCT infeasible. In 
brief, the steps of this approach are (1) to estimate both the 
ITT and (2) per-protocol parameters in the higher-incidence 
setting, then (3) to generalize the per-protocol parameter es-
timate to the lower-incidence setting, and finally and innova-
tively (4) to estimate the ITT in the lower-incidence setting by 
combining the generalized per-protocol estimate with infor-
mation on observed compliance in the target setting. Although 
we believe this approach has many potential applications, we 
describe here how it might be implemented for the example 
described by Adimora et al.1, namely, determining the effec-
tiveness of pre-exposure prophylaxis (PrEP) as prevention for 
human immunodeficiency virus (HIV) transmission. We pro-
vide a summary of simulation experiments that detail how the 
proposed approach works in typical sample sizes, and we give 
examples of the types of variables one would need to measure 
and include when adapting our approach to real-world data.
THE MOTIVATING EXAMPLE
PrEP has been shown in some populations to be effec-
tive at preventing transmission of HIV. For instance, among 
men who have sex with men (MSM), tenofovir/emtricitabine 
reduced incidence of HIV by 44% compared to placebo 
(hazard ratio [HR]: 0.56; 95% CI = 0.37, 0.85).2 One trial in 
serodiscordant, heterosexual couples in Kenya and Uganda 
found that tenofovir/emtricitabine reduced HIV incidence by 
75% compared to placebo (HR: 0.25; 95% CI = 0.13, 0.45).3 
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However, we currently have a limited understanding of how 
well PrEP prevents HIV among women in the United States.
There are two potential reasons for the lack of informa-
tion on the effectiveness of PrEP among US women. First, it 
would be infeasible to conduct a phase III RCT in this popula-
tion because the incidence of HIV is too low. Even among US 
women at exceptionally high risk, whose HIV incidence rate 
was found by one prior study to be 320/100,000 person-years,4 
one would need to enroll 10,000 women to have adequate 
statistical power to detect the same effectiveness observed in 
MSM.1 This would be infeasible not just because of the required 
sample size but also the difficulty of enrolling women who are 
at highest risk for HIV in the United States. Second, results 
from populations of women in Southern Africa, where inci-
dence rates have been observed to be as high as 5700/100,000 
person-years,5 are likely not directly generalizable to US 
women. There is concern regarding generalizability because 
distributions of key demographic, socioeconomic, clinical, 
and behavioral factors are likely to differ between US women 
and African women at risk for HIV. Generalization of results is 
made even more difficult because the trials conducted in Af-
rican women (e.g., the FEM-PrEP [Preexposure Prophylaxis 
Trial for HIV Prevention among African Women] and VOICE 
[Vaginal and Oral Interventions to Control the Epidemic] tri-
als) had to be stopped owing to the lack of demonstrated effec-
tiveness of tenofovir/emtricitabine.5,6 In these trials, adherence 
to study protocol was only 30% to 40%, so the observed ITT 
analyses were essentially futile (i.e., undetectable regardless of 
actual efficacy). A dditionally ( and m ore i mportantly f or o ur 
purposes), the differences between African and US women in 
demographic, clinical, and behavioral factors make it likely 
that the adherence patterns observed in the African trials differ 
from what would be seen among US women.
We can overcome the above challenges by combining key 
data (particularly a valid measure of adherence) from both the 
higher-incidence African and lower-incidence US settings with 
modern analytic methods to obtain both the per-protocol and 
ITT effects in the target population under stated assumptions.
METHODS
The Proposed Approach
Our approach consists of four steps: (1) obtain the ITT 
and (2) per-protocol effects in the higher-incidence African set-
ting,7,8 (3) generalize the per-protocol results to the lower-inci-
dence US setting, and (4) estimate the ITT effect in the United 
States. Although per-protocol results have been generalized to a 
target population,9 to our knowledge the last step is novel.
Before conducting the analyses, we generated 2000 
sim-ulations of the two populations of interest. Our higher-
incidence sample mimicked a placebo-controlled RCT of 
the effect of tenofovir/emtricitabine on prevention of HIV 
transmission in 4000 women in Southern Africa 
(specifically, the FEM-PrEP and VOICE trials).5,6,10 Our 
lower-incidence sample mimicked 
a RCT of 500 women in the United States (with variable dis-
tributions being informed by HPTN 064).4,11,12 In both set-
tings, the populations were women at risk of acquiring HIV, 
with the expectation that some but not all women would be in 
serodiscordant partnerships. In each trial, we randomized half 
the participants to receive tenofovir/emtricitabine and half to 
placebo and, if they were assigned to PrEP, determined their 
adherence (treated simply as a binary variable). In Africa, half 
of the women randomized to PrEP were expected to take it at 
a level required by the study protocol, e.g., a stipulation that 
women take 80% to 90% of dispensed pills or have 10 ng of 
tenofovir per milliliter of plasma.6 In the United States, 75% 
of those randomized to PrEP were expected to follow pro-
tocol, using the same definition as in Africa. Whether women 
adhered was dependent on the woman’s age (defined as >21 
years or not). We then simulated whether they acquired HIV 
12 months after randomization, based on adherence, age, and 
the interaction between adherence and effect measure modi-
fier lack of a sexually transmitted infection (STI) at baseline. 
Lack of an STI was selected as our example modifier because 
the distribution of STIs differs between the two settings and 
having an STI increases risk of acquiring HIV.13–16 Figure 1 
illustrates the causal relationships between the example vari-
ables included in our simulation.17
Starting with the higher-incidence African setting, our 
first parameter of interest was the ITT effect of randomization 
to PrEP versus placebo on HIV incidence. We estimated the 
ITT risk ratio (RR) in two ways: (1) using a log binomial gen-
eralized linear regression model and (2) using the Snowden 
adaptation of Robin’s generalized computational algorithm 
formula (g-formula).18 It was not necessary to include any 
covariates in the models to estimate the ITT.
To account for noncompliance in the PrEP arm, we then 
obtained an estimate of the effect of remaining adherent to 
trial protocol on HIV seroconversion in the African trials, 
i.e., the per-protocol parameter. This method corrects for ad-
herence by analytically censoring participants when they no
longer adhere to trial protocol, following a predetermined rule
FIGURE 1. Causal diagram used in simulations, showing re-
lations between randomization to preexposure prophylaxis, 
adherence to study protocol, lack of sexually transmitted in-
fection (STI) at baseline (an example effect measure modifier), 
age >21 years (an example confounder), and human immu-
nodeficiency virus (HIV) seroconversion. In our simulation, 
older age was positively associated with adherence to pro-
tocol; older age, adherence, and the interaction between lack 
of an STI and adherence were negatively associated with HIV 
seroconversion.
such as described above. Because this process involves anal-
ysis of adherence to protocol, which is by definition a post-
randomization variable (and is not guaranteed to be balanced 
across the trial arms), we must account for (but not stratify on) 
those variables that confound the relationship between pro-
tocol adherence and the outcome.7,8,19
The first method we used to estimate the per-protocol 
effect was a log binomial model among women who adhered 
to the protocol, weighted to represent the entire trial using 
stabilized inverse probability of censoring weights.8 Vari-
ables included in the censoring weight models were those that 
affect adherence and the outcome, so our weight models in-
cluded our example confounder age. The second method was 
g-computation. The key to using the g-formula to estimate the 
per-protocol effect is in specifying the counterfactuals being 
compared: (1) set all participants to receive PrEP and adhere 
to protocol versus (2) set all participants to receive placebo.20 
When modeling the outcome, the model must include con-
founders of compliance and the outcome. Using the para-
metric g-formula (g-computation), we estimated risk of the 
outcome under counterfactual 1 and under counterfactual 2 
and then compared those risks to obtain the RR.
After estimation of the per-protocol effect in the higher-
incidence African setting, one can standardize the results to 
the target population using the known distributions of effect 
measure modifiers that differ between the populations.21 In 
our scenarios, lack of an STI was our example baseline effect 
measure modifier. We again estimated this parameter in two 
ways. First, we estimated stabilized inverse odds of selection 
weights in a combined data set of the African and US trials, 
where selection was defined as inclusion in the African trial. 
The only variable that needed to be included in the weight 
models was lack of an STI.22 Those weights were multiplied 
by the censoring weights, and we ran inverse-probability-
weighted log binomial models in the African data to obtain 
the RR for the per-protocol estimate generalized to the lower-
incidence US setting. Second, we adapted our g-computation 
approach for the per-protocol estimate to include an initial step 
where we took a weighted sample from the African women, 
where participants were selected with replacement and with 
a weight determined by our previously estimated inverse odds 
of selection weights. This ensured that, although the distribu-
tion of all other variables remained the same as in African, the 
distribution of any baseline modifiers would be (on average) 
the same as in the United States. The per-protocol effect was 
then estimated in the same way as above but now within this 
weighted sample.
In the final step, we obtained the ITT effect generalized 
to the United States, using the reweighted African sample. We 
did this by combining information on adherence in the target, 
lower-incidence US setting with the g-computation estima-
tors of the generalized per-protocol parameter. This involved 
adding a step in which we used the US data to model adher-
ence among those randomized to PrEP. The coefficients from 
this US adherence model were then used when generating the 
outcomes, instead of using the coefficients from the African 
adherence model. Finally, we obtained RRs by comparing the 
risks under the scenarios where (1) all participants were set to 
receive PrEP but adherence was allowed to be what it would 
have been in the United States and (2) all participants were set 
to receive placebo.
Several assumptions are required to identify the effects 
of interest in our approach. For all four steps, one must 
assume that the treatment is well defined (i.e., there is no in-
terference and any variations in treatment are irrelevant),23,24 
there is no measurement error, and all models are correctly 
specified. Perhaps more importantly for the design of a study 
seeking to use our approach, one must make the assumption 
of conditional exchangeability for internal validity25 and its 
external validity counterpart.26 For the ITT effect, random-
ization of treatment grants exchangeability in expectation. 
When estimating the per-protocol effects in steps 2 and 3, 
one has to assume that all confounders of adherence to pro-
tocol and the outcome have been accounted for, to ensure 
that those who adhered to protocol in the treatment arm are 
conditionally exchangeable with those who adhered to pro-
tocol in the comparator arm. Analogously, when generalizing 
to the target setting in steps 3 and 4, one has to assume that 
all baseline effect measure modifiers which also affect selec-
tion into one setting versus another have been accounted for, 
to ensure conditional exchangeability between those selected 
into the source population (higher-incidence setting) and 
those not selected (lower-incidence setting). Lastly, one has 
to assume there is a positive probability of being observed in 
all strata defined by the treatment (or, for external validity, se-
lection) and those variables necessary to achieve conditional 
exchangeability.26–28
Below we provide the results summarized across 2000 
simulations. Key population variables are summarized using 
the median and interquartile range (IQR) of the percentages 
in each simulation. We then report the RR at each step aver-
aged across the simulations, alongside the 2.5th and 97.5th 
percentiles (hereafter referred to as the 95% central mass) of 
the 2000 RRs. We additionally give Monte Carlo simulation 
errors for each parameter, estimated by the standard error of 
the simulation RRs.
All analyses were conducted in SAS version 9.4 (SAS 
Institute, Cary, NC). Technical details on how each step was 
carried out using g-computation and SAS code are given in 
the eAppendices (http://links.lww.com/EDE/B458).
RESULTS
As shown in Table 1, across the 2000 simulations, 50.0% 
(IQR: 49.5%–50.5%) of the 4000 women enrolled in the Af-
rican trial were randomly assigned to PrEP, but only 24.9% 
(IQR: 24.4%–25.4%) of the 4000 women actually received 
PrEP. One third (33.3%; IQR: 32.9%–33.9%) were >21 years 
of age, and 79.0% (IQR: 78.6%–79.4%) tested negative for 
an STI at baseline. At 12 months, 4.2% (IQR: 4.0%–4.4%) of 
African women acquired HIV.
In the lower-incidence US setting, again half (50.0%; 
IQR: 48.6%–51.4%) of the 500 women were randomized to 
receive PrEP, and 37.0% (IQR: 35.4%–38.4%) of the 500 
women took PrEP. The US women were older than those in the 
African setting (66.6% >21 years of age; IQR: 65.4%–68.2%) 
and more likely to test negative for an STI at baseline (89.0%; 
IQR: 88.2%–90.0%). The 12-month risk of HIV infection in 
US women was 0.4% (IQR: 0.2%–0.8%).
Table 2 provides the average and 95% central mass of 
the 2000 simulation parameter estimates obtained using the 
g-computation approach, and Figure 2 displays the full distri-
bution of 2000 simulation RRs. We found that the risk of HIV
infection in African women randomized to PrEP was 0.65
(95% central mass: 0.47, 0.88) times the risk among women
randomized to placebo. The risk of HIV infection among Af-
rican women who remained adherent to study protocol and
took PrEP was 0.20 (95% central mass: 0.08, 0.34) times the
risk among women who stayed on study protocol but took pla-
cebo. As expected, the ITT effect was closer to the null than
the per-protocol effect because low adherence in the PrEP arm
attenuated PrEP’s protective effect.
As for the generalized effect estimates, the risk of HIV 
infection in US women randomized to PrEP was 0.42 (95% 
central mass: 0.20, 0.62) times the risk among women ran-
domized to placebo, and the risk among US women who 
remained adherent to study protocol and took PrEP was 0.17 
(95% central mass: 0.03, 0.38) times the risk among women 
who stayed on protocol but took placebo. Both the US ITT 
and per-protocol results were further from the null than the 
African results because more of the US women tested neg-
ative for an STI at baseline, and lack of an STI was asso-
ciated with a more protective treatment effect. Additionally, 
for the ITT effect, US women were more likely to adhere to 
PrEP (partly because they were older), which resulted in a 
stronger protective effect of PrEP than in Africa where adher-
ence was lower. The Monte Carlo simulation errors (defined 
as standard errors of the simulation RRs) were <0.01 for all 
four parameters.
To assess the performance of our approach, we used 
several different comparators. First, we saw that the param-
eters estimated using log binomial models and, for the per-
protocol effects, inverse-probability-weighting methods 
were comparable (eTable 1; http://links.lww.com/EDE/
B458). The generalized US ITT parameter was not estimated 
using weighting methods (to our knowledge, no such meth-
ods currently exist) and could not be compared. Second, we 
generated counterfactual outcomes for each individual in 
each simulation under the ITT and the per-protocol. We then 
estimated the true RRs in Africa and in the US by dividing 
the average of the counterfactual outcomes. For Africa the 
true ITT RR was 0.64 and the true per-protocol RR was 0.20; 
for the US those RRs were 0.44 and 0.17, respectively. Thus, 
all four of our g-computation estimates were close to the true 
parameter values.
Last, we compared our generalized results to what 
would have been obtained had we enrolled 10,000 women in 
the US – the estimated sample necessary to have adequate sta-
tistical power to detect the effect size observed in trials among 
MSM. Consequently, this is a large enough population that 
effects could be estimated without generalization. We applied 
the same methods used to estimate the African ITT and per-
protocol effects and found that the ITT and per-protocol 
effects in this large US trial were 0.41 and 0.13, respectively. 
These results (given in Table 2) again matched closely those 
obtained using our generalization approach.
TABLE 1. Distributions of Key Variables Across 2000 
Simulations in the Higher HIV Incidence African Setting and 
Lower-Incidence US Setting
Variable
African Trials (n = 4,000)
Median (IQR) (%)
US Trials (n = 500)
Median (IQR) (%)
Randomization to PrEP 50.0 (49.5–50.5) 50.0 (48.6–51.4)
Receipt of PrEP 24.9 (24.4–25.4) 37.0 (35.4–38.4)
Incident HIV 4.2 (4.0–4.4) 0.4 (0.2–0.8)
Age >21 yearsa 33.3 (32.9–33.9) 66.6 (65.4–68.2)
No STI at baselineb 79.0 (78.6–79.4) 89.0 (88.2–90.0)
HIV indicates human immunodeficiency virus; IQR, interquartile range; PrEP, 
preexposure prophylaxis; STI, sexually transmitted infection (other than herpes simplex 
virus)
aAfrican age distribution based on Refs. 6 and 10. US age distribution based on 
Refs. 4 and 11.
bAfrican distribution based on Ref. 10, and US distribution based on Ref. 12.
TABLE 2. Intention-to-Treat and Per-Protocol Effects in the Higher HIV Incidence African Setting and in the Lower-Incidence US 
Setting as Estimated Using G-computation to Generalize from the African Trial and Directly Estimated in an Impractically Large Trial
Parameter
African Trials (n = 4,000)
RR (2.5th–97.5th)
US/African Composite 
Trials (n = 500/4,000)
RR (2.5th–97.5th)
US Trial (n = 10,000)
RR (2.5th–97.5th)
Intention to treat 0.65 (0.47–0.88) 0.42 (0.20–0.62) 0.41 (0.19–0.68)
Per protocol 0.20 (0.08–0.34) 0.17 (0.03–0.38) 0.13 (0.00–0.31)
2.5th represents 2.5th percentile of the 2000 simulation RRs or, for the US trial, of 500 bootstrap resamples. 97.5th represents 97.5th percentile of the 2000 simulation RRs or, for 
the US trial, of 500 bootstrap resamples.
HIV indicates human immunodeficiency virus; RR, risk ratio.
of adherence were different. That adherence is a postrandom-
ization variable on the pathway between randomization and 
the outcome means that it must be carefully handled during 
the analysis. Estimation of the per-protocol effect is one way 
to validly account for adherence, after which generalization 
can be carried out in the usual way. The generalized per-
protocol effect can then be tweaked using measured data on 
adherence in the lower-incidence target population to back-
calculate the ITT effect.
There were of course several limitations of this simula-
tion. Primarily, our design was simplified, with only one time 
point and an unrealistically small variable set. Future appli-
cations of our approach will likely have many time points 
at which they assess adherence and HIV incidence, and use 
of such data will require adequately accounting for time-
varying adherence and time-varying confounders. However, 
although we do not show it here, the methods used at each 
step can be extended to handling the time-varying case, and 
we plan in future work to adapt our approach to these more 
complex settings.29 Moreover, assessment of variables in real 
trials will generally not be as clean cut as shown here. For 
instance, adherence can be difficult to measure, being highly 
prone to measurement error, and may not always be a yes/no 
binary variable. We also constructed our example such that 
all women in both samples remained in the study until the 
outcome was assessed and that there were no missing data; 
no actual trial is likely to be so perfect. As above, though, our 
approach could be extended to account for censoring or for 
missing data. Additionally, we did not demonstrate here how 
to obtain confidence intervals for the estimated RRs. When 
adapting our approach, one way to obtain valid confidence 
intervals would be to use bootstrap.
Above we discussed the assumptions necessary for our 
approach. Whether these assumptions are reasonable will be 
context dependent and will in part rely on careful study de-
sign and data collection. For instance, here we only included 
the minimal number of variables necessary to demonstrate the 
approach. When using our approach, a researcher will need to 
carefully consider the context and question of interest to de-
termine the variable set sufficient to meet the exchangeability 
assumption. For instance, although we only examined base-
line STI, a researcher using our approach might also attempt 
to capture whether a woman was in a sero-discordant part-
nership or frequency of condom use, so these could also be 
used as effect-measure modifiers. Our goal, though, as proof 
of concept, was simply to give examples of the types of vari-
ables one would need.
Furthermore, a particular implication of the no measure-
ment error assumption worth highlighting is the requirement 
of using a valid measure of adherence in both populations 
when estimating the per-protocol effect. Although we simply 
used an arbitrary, dichotomized indicator of adherence to pro-
tocol, an investigator would ideally have an accurate measure 
of drug concentration, by which they could ascertain whether 
FIGURE 2. Boxplots of the simulation risk ratios with indi-
vidual simulation estimates for all four parameters estimated 
using g-computation. The filled diamonds are the t rue risk 
ratios, and the unfilled diamonds are the estimated risk ratios. 
The boxes represent the interquartile range, with the me-
dian risk ratio being the line within the box. Each of the light 
gray circles represents the result from a single simulation. The 
breadth of the whiskers is 1.5 times the interquartile range. 
Extreme outliers were removed from the picture (for the US 
intention-to-treat [ITT], 15 risk ratios <1 × 10−4 and, for the US 
per-protocol, 15 risk ratios <1 × 10−10).
DISCUSSION
Here, we proposed an approach to generalize ITT and 
per-protocol effects from a higher-incidence setting to obtain 
estimates of those same effects in a lower-incidence setting. 
In our example, HIV incidence in the United States was not 
high enough to permit estimation of these effects without 
enrolling an impractically large sample, but, using key data 
from a trial of African women alongside modern statistical 
methods, we were able to estimate both the generalized per-
protocol and ITT effects. Our results were consistent across 
different estimators, i.e., the g-computation results matched 
results obtained using inverse-probability-weighting methods. 
Furthermore, our per-protocol results were comparable to the 
“true RR” estimated from the individual counterfactual out-
comes, and our generalization results matched those we would 
have seen if we enrolled a trial of 10,000 US women.
An approach like the one described here is necessary 
if the goal is to estimate the ITT effect of a treatment in 
the lower-incidence setting. This is because the ITT is a 
function of the level of adherence within a population. 
Therefore, if one generalized the ITT from the higher-
incidence setting to the lower-incidence setting (which 
requires measuring in both settings and analytically 
controlling for the necessary effect measure modifiers), the 
result would be biased if the patterns  
a woman received an effective dose of the drug.30 This infor-
mation would then guide the formulation of the trial’s protocol 
regarding adherence. If an effective concentration was not 
known, the investigator could examine different cut points for 
drug concentration and compare the results of our approach 
for each cut point.
Some practical implications of our approach should also 
be noted. In our motivating PrEP example, the high-incidence 
trials from which we would generalize to the United States al-
ready exist. Thus, it would save a great deal of time and money 
to enroll the small US trial and apply our approach to estimate 
the desired parameters, in comparison to enrolling the 10,000 
woman trial and estimate the parameters more directly. How-
ever, if our approach were to be used in scenarios where a high 
incidence study does not exist, this choice would not be so 
clean cut. The investigators would need to weigh the costs of 
designing and conducting studies in both settings sequentially 
or concurrently (as well as the “cost” of making the neces-
sary assumptions for our statistical approach) against the cost 
of running one larger study in the low incidence setting. This 
decision will likely be context-dependent, hinging on factors 
such as how large the study in the low-incidence setting would 
need to be (which would depend on the outcome incidence) 
and how well the investigators believe they could measure all 
the necessary variables to carry out our approach.
Despite its limitations, the proposed approach has the 
potential to be applied to a number of important public health 
questions. For instance, to return to our motivating example, 
understanding how well PrEP can prevent HIV incidence 
among at-risk women in the United States is an understud-
ied but critical area of research. Assessment of PrEP efficacy 
in this population would require an impractically large trial 
because incidence is as low as 320 infections per 100,000 
person-years (compared to 5700/100,000 person-years in 
Sub-Saharan Africa).4,5 However, our approach would allow 
researchers to estimate PrEP effectiveness while enrolling a 
much smaller trial of US women partly because it does not 
rely on measuring the outcome in the United States.
Moreover, our approach need not be limited to 
pla-cebo-controlled RCTs in both settings. The strategy 
could be adapted for studies using an active comparator; such 
situations would require measuring adherence to the active 
comparator and accounting for this adherence in the per-
protocol effect estimation. Observational studies could also 
serve as the data source. In an observational study, the ITT 
effect might com-pare women who were prescribed PrEP 
by a physician to a similar group of women who were not 
prescribed PrEP. Es-timation of the per-protocol effect 
would, as in our example, require an accurate measure of 
adherence to PrEP. The use of observational data, however, 
would mean PrEP was no longer randomized, and 
exchangeability would no longer be expected when 
estimating the ITT. A researcher would thus need to ad-
ditionally control for the confounders of being 
prescribed PrEP and HIV incidence. Accurate measures of 
all required  
variables (adherence, confounders, and effect measure modi-
fiers) might also be more difficult to attain than in an RCT.
Thus, the simulations described here, while limited, in-
form the design of future studies that seek to examine the ef-
fectiveness and efficacy of a treatment (like PrEP) not just in 
higher-incidence settings but also in lower-incidence settings 
where a traditional RCT would not be feasible.
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